By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The stocks of many genomic tools and molecular diagnostics vendors took a hard hit for the second month in a row as the broader stock market continued its slide in August.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.